Brensocatib Shows Promise for Bronchiectasis Treatment,‍ Dosage Matters

Updated June 02, 2025

new ‌research indicates that varying doses of brensocatib can effectively treat bronchiectasis, with the​ specific ⁤dosage influencing patient outcomes. The findings, presented at ⁢the American⁢ Thoracic Society 2025‍ international Conference, ⁢highlight the drug’s potential in managing this chronic ⁣condition.

Dr.‍ James ​Chalmer, chair of ⁣Respiratory Research, Cardiology, at the University of Dundee in Scotland, discussed the results of the phase 3 ASPEN⁢ trial. The trial,​ sponsored⁢ by Insmed Incorporated, examined the impact of different brensocatib ⁤dosages on individuals‍ with bronchiectasis.

The ASPEN trial, the largest of its kind for bronchiectasis, randomized patients to receive either 25 mg of brensocatib, 10 mg of brensocatib, or a placebo⁣ over 52 weeks. The primary⁤ focus was on the frequency of exacerbations, with secondary outcomes including lung function decline (FEV1) and symptom changes measured⁤ via quality of ⁢life questionnaires.

The⁢ study revealed that ​both the 10-mg⁢ and 25-mg doses led to an approximate 20% reduction in exacerbation frequency‌ compared ⁢to the placebo. Notably, the 25-mg dose also ⁢demonstrated a slowing in the rate of ​FEV1 ‍decline, suggesting a protective‍ effect ⁣on​ lung⁤ function.

Subgroup analyses further explored the drug’s effectiveness ‌in specific patient populations, including those using long-term ⁤macrolide treatment, individuals with elevated blood eosinophil counts, and ⁢adolescents.

The analysis showed that brensocatib’s ‌benefits remained ⁣consistent whether or not patients were⁤ already using macrolides. This suggests that⁢ brensocatib can be used⁣ independently or as an add-on therapy.

The study also found that patients with high ​blood eosinophil levels experienced similar benefits ‌to those ‌with low levels, indicating that brensocatib’s effectiveness is not affected by eosinophilic ​inflammation.

Data from the ⁤adolescent subgroup (ages‍ 12-18) revealed exacerbation⁣ reductions comparable‌ to those seen in adults. Furthermore, brensocatib appeared to prevent the high rate of lung function decline observed in the placebo group.

⁤ The overall findings ‌showed an approximate 20% reduction in exacerbation frequency with both the 10-mg and the ​25-mg dose compared ⁣to placebo.

What’s next

These findings pave the way for potential⁢ new treatment strategies for bronchiectasis, particularly concerning brensocatib’s role⁢ in slowing lung function⁢ decline ⁤and reducing exacerbations across diverse patient subgroups. Further research may‍ focus on optimizing‌ dosage and identifying specific patient profiles ​that benefit most ⁤from brensocatib treatment.